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Abstract: Early diagnosis of Alzheimer’s disease (AD) is a crucial starting point in disease management. Blood-based biomarkers could represent a considerable advantage in providing AD-risk
information in primary care settings. Here, we report new data for a relatively unknown blood-based
biomarker that holds promise for AD diagnosis. We evaluate a p53-misfolding conformation recognized by the antibody 2D3A8, also named Unfolded p53 (U-p532D3A8+ ), in 375 plasma samples
derived from InveCe.Ab and PharmaCog/E-ADNI longitudinal studies. A machine learning approach is used to combine U-p532D3A8+ plasma levels with Mini-Mental State Examination (MMSE)
and apolipoprotein E epsilon-4 (APOEε4) and is able to predict AD likelihood risk in InveCe.Ab
with an overall 86.67% agreement with clinical diagnosis. These algorithms also accurately classify
(AUC = 0.92) Aβ+ —amnestic Mild Cognitive Impairment (aMCI) patients who will develop AD
in PharmaCog/E-ADNI, where subjects were stratified according to Cerebrospinal fluid (CSF) AD
markers (Aβ42 and p-Tau). Results support U-p532D3A8+ plasma level as a promising additional
candidate blood-based biomarker for AD.
Keywords: blood-based biomarker; Alzheimer’s disease; machine learning; β-amyloid; conformation
variant of p53

Copyright: © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This

1. Introduction

article is an open access article distributed

Alzheimer’s disease (AD) is a progressive and devastating neurodegenerative disease
affecting nearly 50 million elderly worldwide [1]. This clinical syndrome is characterized
by a progressive deterioration in cognitive and functional abilities, leading to impaired
everyday activities and eventual death. Delayed diagnosis, the lack of efficacious therapies,
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and the associated chronic disability render the disease a calamity [2]. Although significant
efforts have been directed toward the identification of potential pharmacological targets,
no disease-modifying therapy has yet been approved. Among the contributing reasons
for these failures is the absence of biomarkers for the early detection and the biological
stratification of the participants in clinical studies [2]. Biomarkers are also needed to identify
high-risk individuals before cognitive symptoms manifest, allowing early interventions
before the brain is irreversibly damaged.
It is now well established that clinical manifestations of AD are preceded by a long
preclinical stage, during which pathophysiological processes might occur not only in the
brain [3,4] but also at the periphery [5,6]. During this period, therapies might be most
effective to prevent, slow, or even stop the disease.
One of the well-recognized upstream events in AD pathogenesis is amyloid β protein
(Aß) deposition in the brain; although it is insufficient to cause cognitive deterioration,
it may be sufficient to induce downstream pathological changes that ultimately lead to
cognitive deterioration [7]. A widely held view is that amyloid biomarkers represent
the earliest evidence of AD neuropathological changes currently detectable in living persons [7]. Cerebrospinal fluid (CSF) Aß levels and amyloid PET scanning are validated
early biomarkers of AD, but the invasive nature of the former and the high cost of the
latter limit their application. Blood-based biomarkers represent promising solutions for AD
diagnosis and research since they could provide a non-invasive test to be used in the first
steps of the diagnostic workflow, ruling out those subjects who do not have underlying
AD pathophysiology from further analyses [8,9]. In the discovery of such biomarkers,
one strategy has been to seek in blood what is already known in the brain. Although for
many years identifying meaningful Aß biomarkers in blood has been a challenge, recently,
highly sensitive and precise assays for its measurement in plasma, strongly reflecting
brain amyloidosis, have emerged [10]. However, some individuals with normal CSF-Aß or
negative amyloid PET progress to AD, strongly suggesting the need to explore alternative
and complementary biomarkers.
We previously demonstrated that p53 conformational alterations were found in different cell types derived from AD patients (fibroblasts, immortalized B lymphocytes,
and peripheral blood mononuclear cells (PBMCs)) as well as in in vitro and in vivo models [11,12], using several experimental approaches. More recently, we demonstrated that,
upon different redox stressors exposure, several misfolding p53 conformations can exist [13]
with different affinity for different anti-p53 antibodies. Here, we propose the detection in
plasma of a misfolding p53 conformational variant recognized by the novel conformational
antibody 2D3A8 (U-p532D3A8+ ) as a predictive biomarker of AD risk. Although p53 has
been seen for more than two decades as implicated in the cell death occurring in neurodegeneration, a growing body of evidence supports the notion that p53-induced adaptive
responses, including immune response control, redox balance, and neurite rearrangement,
are instead gradually dysregulated during the AD continuum [14–21]. Recently, several
research studies have described the pleiotropic role of functional/unfunctional p53 in the
brain and its possible role in AD pathogenesis, describing how dysregulated p53 signaling
and the loss of its canonical biological function may exacerbate AD pathology [22].
The expressions of APP and ß-secretase (BACE1) are negatively regulated by p53 [23],
corroborating the contribution of p53 to preventing APP pro-amyloidogenic process. The
link between γ-secretase members and p53 is more complex. p53 is regulated by and
regulates members of the γ-secretase complex. In particular, p53 increases the expression
of presenilin enhancer 2 (Pen-2), which, in turn, negatively regulates p53 expression. Presenilin 1 is also a negative regulator of p53, whereas presenilin 2 increases p53 transcriptional
activity. Together, these findings highlight p53 as a tight regulator of APP processing [24].
In the present work, for the first time, we tested and validated the antibody 2D3A8
for the detection of a p53-misfolding conformation in plasma samples derived from two
different longitudinal cohorts where prodromal and preclinical AD were included. Using a
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machine learning approach that combines U-p532D3A8+ plasma levels with clinical variables,
we developed an algorithm able to stratify AD risk.
2. Materials and Methods
2.1. Participants and Clinical Phenotyping
Participants were aged between 60 to 80 years old. We analyzed 375 blood samples
derived from single-center Italian studies and a multicenter cohort in Europe. These
included 264 plasma samples selected from InveCe.Ab, a 4 year longitudinal study in a
population of community-dwelling elderly inhabitants of Abbiategrasso, Italy [25], and 111
plasma samples from PharmaCog/E-ADNI, a European multicenter memory-clinic-based
study involving amnestic Mild Cognitive Impairment patients (aMCI) [26].
Cohort’s characteristics are summarized in Table 1, and the design of the entire
InveCe.Ab study is reported in Table S2.
Table 1. Demographic and clinical profile of the subjects. Demographic and clinical variables
and genotype frequency of the APOEε4 polymorphisms of all the subjects. N: number; M: male;
F: female; MMSE: Mini-Mental State Examination; CN: cognitively normal subjects; MCI: mild
cognitive impairment; aMCI: amnestic mild cognitive impairment; AD: Alzheimer’s disease; CSF:
cerebrospinal fluid. Data are expressed as mean ± standard deviation (SD). For female prevalence
and genotype, absolute frequencies (%) are reported.

No. plasma samples
Classification
N. subjects
Sex: female, n (%)
Age, mean (SD)
APOEε4 status, n (%)
Level of education (SD) b
MMSE (SD)
Conversion to AD, N
Conversion time (min–max), months
AD-related biomarkers
CSF Aβ42 level (SD), pg/mL
CSF p-Tau level (SD), pg/mL
CSF t-Tau level (SD), pg/mL

InveCe.Ab

PharmaCog/E-ADNI

264 *
CN
MCI
64
26
37 (57.81%)
8(30.77%)
73 (1.22)
73.28 (1.36)
14 (21.87%)
8 (30.77%)
1.14 (0.65)
1.16 (0.54)
27.56 (2.28)
26.5 (2.11)
10/64
9/26
24–48
24–48

111
aMCI
111 a
64 (57.66%)
69.12 (7.55)
52 (46.85%)
1.37 (0.50)
26.41 (1.83)
18/111
6–30
676.41 (290.72)
70.31 (36.98)
503.82 (373.44)

* Baseline, T1 , and T2 plasma samples. Missing plasma samples at T1 (2 Stable MCI and 1 MCI-to-AD)
and at T2 (3 MCI-to-AD already converted at T1 ); a Missing CSF (1); b Level of education was assigned
as follows: illiterate (0), from 3 to 12 years (1), from 13 to 18 years (2), and more than 18 years (3).

In detail, in InveCe.Ab, frozen EDTA-Plasma samples derived from 64 cognitively
healthy subjects (CN) and 26 MCI were available from three sampling periods 2 years apart
(Baseline, T1 and T2 ) during a 4-year follow-up [25] (Tables S3 and S4). AD was diagnosed
using the National Institute of Neurological Disease and Communicative Disorders and
Stroke–Alzheimer’s Disease and Related Disorders Association (NINCDS/ADRDA) criteria [27] and based on the diagnostic workup according to the European Federation of
Neurological Societies guidelines [28]. In PharmaCog/E-ADNI, thirteen clinical centers
consecutively recruited 147 aMCI patients, of whom 111 were included in this study. The
neuropsychological battery test and inclusion and exclusion criteria have been described
elsewhere [26]. Baseline CSF and blood were preprocessed, frozen, and stored at each
site according to a standardized protocol and in line with the Alzheimer’s Association
quality control program [29]. Clinical diagnosis of neurodegenerative disorders was made
according to the conventional criteria [27,30,31]. For CSF biomarker, we used published
cutoffs (Aβ42 < 550 pg/mL, t-Tau > 225.6 pg/mL, and p-Tau > 52 pg/mL) [26,32,33].
The two cohorts were chosen according to the context of use (COU) to investigate and
the outcomes for which the single cohort was designed (conversion to AD, Aβ status). For
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the InveCe.Ab study, the outcome was the evaluation of U-p532D3A8+ in relation to ADconversion, both in non-demented subjects and in subjects with mild cognitive symptoms
(MCI), classified according to clinical international criteria [27]. For PharmaCog/E-ADNI,
the outcomes were the correlation of U-p532D3A8+ with: (i) AD-associated brain pathological
changes (i.e., CSF AD biomarkers) and (ii) the rate of MCI-to-AD conversion according to
their Aβ status.
In addition, 114 plasma samples from the population-based study ANZIANI INRETE [34], a randomized sample of the elderly population of Brescia, Italy, affected by
different chronic diseases and multi-morbidities, were also tested to evaluate U-p532D3A8+
distribution in age-related co-morbidities. More information in Supplementary Materials.
All the studies were approved by the appropriate institutional ethics committee,
and all the participants gave written informed consent. InveCe.Ab: Clinical trials.gov,
NCT01345110; ANZIANI IN-RETE: reference number 0144116; Pharmacog/E-ADNI:
parere 36/2010.
2.2. Sample Size Considerations for InveCe.Ab
The power calculation and sample size estimation were performed in accordance
with the AD conversion rate within the InveCe.Ab study: among 1039 CN at baseline,
10 converted to AD (0.96%), and among 101 MCI, 10 converted to AD (9.9%) within 4 years.
The effect size was estimated based on the observation that at T2 , 692 were stable CN
and 40 were MCI. The multiple regression power calculation of sample size considered
6 independent variables (Sex, Education level, Age, APOEε4, MMSE, plasma_U-p532D3A8+ ),
the effect size of 0.666 for stable CN and 0.5882 for stable MCI, a sensitivity > 80% and
a theoretical sensitivity of 50% (statistical power of 0.8 and a significance level of 0.05).
Therefore, using this analysis in addition to the 20 converters of the longitudinal study, the
number of stable CN and MCI would have been not less than 20.4 (∼
=21) and 23.09 (∼
=23)
subjects, respectively. The different subgroups were then selected according to age, gender,
comorbidities index, severity index, and clinical category matched.
2.3. Immunoassay for Plasma U-p532D3A8+ Biomarker Analysis
An indirect in-house ELISA with 2D3A8 antibody (epitope aa 282-297) was used to
measure U-p53 in plasma. The 2D3A8 anti-p53 antibody is under patent fully owned by
Diadem srl (PCT/EP2015/072094/family 15122V), and more details about the antibody
are reported in Table S1. More information related to the specificity of 2D3A8 for a
conformational variant of p53 and assay reproducibility are reported in Figures S1–S3.
Briefly, 100 µL of diluted plasma and reference-control peptides at different concentrations were coated on a plate overnight at 4 ◦ C. Results were extrapolated from the peptide
standard curve ranging from 1.87–30 ng. Thus, considering that the evaluation of U-p53
detected by the assay is expressed in relation to a short reference peptide, results have been
expressed in arbitrary units (a.u.) not to confuse the measure with the estimation of p53
protein concentration in human plasma.
2.4. Statistical Analysis
Linear Mixed Effects (LME) [35] regression was used to model U-p532D3A8+ levels
across time, as well as across diagnostic status. We ran two separate models: one comparing
stable CN with CN converting to AD, and the other stable MCI with MCI converting to
AD. The description of the model output is described in Table S6.
A non-parametric method Regression Tree (RT) [36,37], a type of Machine Learning
technique [38,39], was used to deliver an Early Warning System that strongly predicts risk
zones in terms of AD prevalence or Aβ status (ranging from 0—no risk—to 1—maximum
risk). When the dependent variable (Y) is dichotomous, the prediction in each terminal
node is the relative frequencies of 1 in the node itself. The estimation process is based on
the ten-fold cross-validation, through which the data are partitioned into v nearly equally
sized folds, and next running v interactions of training and validation to such an extent
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that within each interaction, a different fold of the data is held out for validation, while
the remaining (v − 1) folds are used for learning. Since InveCe.Ab dataset showed a longitudinal structure, we took advantage of this by using the rolling window procedure [40],
proposed in finance for time series, in order to predict the diagnosis of each patient, where
Sex, Education Level, Age, MMSE, APOEε4 and plasma_U-p532D3A8+ are the covariates.
In detail, the prognostic accuracy of the proposed RT model used in InveCe.Ab is
obtained because the RT is calibrated within a starting window (Baseline—first training set);
then, such model is used to forecast the Alzheimer conversion of patients after two years
(T1 , first out of sample). Since, in the original dataset, AD patients are not available at the
baseline, a small-scale training set [41] has been included. The procedure is repeated, joining
Baseline and T1 (second training set) for the calibration of the model and testing Alzheimer
J. Pers. Med. 2021, 11, x FOR PEER REVIEW
6 of 17
conversion after four years (T2 , second out of samples). A schematic representation is
reported in Figure 1 and additional information in Table S7 and Figure S4.

Figure 1. Statistical framework. The procedure for obtaining the optimal decision tree with a rolling
window
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In order to evaluate the performances of methods introduced in this study, Receiver
3. Results
Operating Characteristic (ROC) analysis is used, extracting additional metrics such as
We tested 264 plasma samples derived from InveCe.Ab [25] with the anti-p53 antibody 2D3A8 to evaluate the expression of a misfolding conformation variant of p53 (Up532D3A8+) during disease progression (Table 1). According to the sample size power calculation that considered the percentage of AD conversion, a total of 64 CN (10 progressed
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Area Under the Curve (AUC), sensitivity, and specificity. Corresponding 95% confidence
interval (CI), computed with 10,000 stratified bootstrap replicates, are reported. Results
obtained are then compared with a well-known parametric model such as Logit, extracting
predictions and computing the same metrics proposed in decision trees. Moreover, rank
correlations [42], test on proportion, Fisher exact test, Wilcoxon rank sum test (U of MannWhitney), Kruskal–Wallis test, ANOVA test, De-Long test were applied. Analyses were
performed using R, version 3.4.4.
3. Results
We tested 264 plasma samples derived from InveCe.Ab [25] with the anti-p53 antibody
2D3A8 to evaluate the expression of a misfolding conformation variant of p53 (U-p532D3A8+ )
during disease progression (Table 1). According to the sample size power calculation that
considered the percentage of AD conversion, a total of 64 CN (10 progressed to AD and
17 to MCI) and 26 MCI (9 progressed to AD) were evaluated. Time-series data for Up532D3A8+ were collected at three time points every two years (Baseline, T1 , and T2 ) using
an in-house immunoassay. Five different groups were considered according to diagnosis at
T2 : Stable-CN, CN converted to MCI (CN-to-MCI) or AD (CN-to-AD), Stable-MCI, and
MCI converted to AD (MCI-to-AD). At baseline, the CN-to-AD converters group showed a
statistically significant elevation of U-p532D3A8+ levels compared with stable-CN, which
was more evident at T1 (p < 0.05) and T2 (p < 0.0001). Differences in U-p532D3A8+ were also
observed at T2 in MCI-to-AD converters compared to Stable-MCI (p < 0.01). An increase
in U-p532D3A8+ plasma levels was found in CN-to-MCI progression (p < 0.0001), linking
U-p532D3A8+ with the worsening of cognitive decline (Table S5).
LME longitudinal analysis showed that the trajectory slope of CN-to-AD converters
was steeper compared to stable CN (Figure 2a), whereas those of Stable MCI and MCIto-AD showed a tendency to overlap (Figure 2b), corroborating that U-p532D3A8+ plasma
levels correlate with the continuum of the disease. ROC curves performed at T2 (after the
conversion) displayed an AUC of 0.99 (sensitivity and specificity = 100%) and an AUC of
0.92 (sensitivity = 88.9% and specificity = 94.1%) in discriminating Stable-CN vs. CN-to-AD
and Stable-MCI vs. MCI-to-AD, respectively (Figure 2c,d).
To test the performance of plasma U-p532D3A8+ in predicting AD-likelihood risk, we
used an integrated regression tree (RT) algorithm, a machine learning technique, with
the rolling window procedure to construct a two-step procedure that provides an early
warning system strongly predicting risk zones of AD prevalence. The tree structure
obtained by RT2 (Figure 3a) selected U-p532D3A8+ plasma levels as the most important
differentiating variable and identified six nodes, representing three AD-likelihood risk
categories. According to the prevalence of AD observations within each node, RT2 classified
nodes 1 and 2 as low-risk (in green), nodes 3 and 4 as middle-risk (in pink), and nodes 5 and
6 as high-risk (in red). Specifically, we found that node 6 (U-p532D3A8+ ≥ 10.05) contained
only AD patients, whereas in node 5 (9.35 ≤ U-p532D3A8+ ≤ 10.05), the AD prevalence was
78%. When U-p532D3A8 + was less than 7.71, the risk of developing AD was very low, since
most of the subjects in node 1 were stable-CN and stable-MCI (Figure S5). Considering the
intermediate U-p532D3A8+ threshold, the algorithm selected two well-known co-variables
associated with AD risk: Mini-Mental State Examination (MMSE) and apolipoprotein E
epsilon-4 (APOEε4). When MMSE ≥ 25.5 and APOEε4 were present, most of the subjects
in node 3 were stable-MCI (37.50%) with a 25% risk of developing AD. In the absence of
this AD genetic predisposing factor, the algorithm classified subjects in node 2 as lo-risk.
Conversely, cognitive decline (MMSE < 25.5) combined with U-p532D3A8+ levels between
7.71 and 9.35 placed individuals in node 4, in which 50% were represented by AD patients
and 20% by AD converters (Figure 3a, Figure S5).

LME longitudinal analysis showed that the trajectory slope of CN-to-AD converters
was steeper compared to stable CN (Figure 2a), whereas those of Stable MCI and MCI-toAD showed a tendency to overlap (Figure 2b), corroborating that U-p532D3A8+ plasma levels correlate with the continuum of the disease. ROC curves performed at T2 (after the
displayed an AUC of 0.99 (sensitivity and specificity = 100%) and an AUC of
J. Pers. Med. 2021, 11,conversion)
14
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(a multimodal classification scheme modified from Jack and colleagues [7]), 110 aMCI
subjects were subdivided into four groups: A− /T− (30), A+ /T− (8), A+ /T+ (36), and
A− /T+ (36). U-p532D3A8+ levels were found to be statistically higher in A+ /T+ (p < 0.001),
A+ /T− (p < 0.05), and A− /T+ (p < 0.01) compared to A− /T− (Figure 4a) and showed an
ROC with an AUC of 0.80 in discriminating A− /T− versus A− /T−/+ (Figure 4b).

Figure 4. U-p532D3A8+ in PharmaCog/E-ADNI subjects stratified according to CSF markers. Subjects were stratified using a
multimodal classification scheme with CSF Aβ42 (A) and p-Tau (T) cutoff reported in the literature. (a) Scatter dot blots
report the value of U-p532D3A8+ in the different groups. The results obtained are represented as mean ± SEM. Red circle:
aMCI to AD, dark gray circle: aMCI to other dementia. After a period of 6 to 30 months, 91 patients remained stable aMCI,
apart from 1 who developed mixed AD + DLB dementia at 24 months (in the group A− /T− ), 1 who progressed to DLB
at 12 months (in the group A− /T+ ), and 18 who progressed to AD in a range of 6 to 30 months (9 in the A+ /T+ group,
1 in the A+ /T- group, and 8 in the A− /T+ group). Wilcoxon test adjusted for multiple comparison: A− /T− vs. A+ /T–
(p < 0.05 *); A+ /T+ (p < 0.001 ***) and A- /T+ (p < 0.01 **). One patient had missing CSF information. (b) ROC curve was
used to distinguish A− /T− versus those subjects with Aβ—positive status (A+ /T+/− ) with an AUC of 0.80. Additional
information on the performance of U-p532D3A8+ in discriminating these groups is reported in Figure S11. Results were
extrapolated from a short-reference peptide standard curve and are expressed as arbitrary units (a.u).

Next, to investigate the ability of plasma U-p532D3A8+ to identify Aβ+ subjects (A+ /
we applied an RT algorithm combining U-p532D3A8+ with MMSE and APOEε4. The
resulting RT identified four distinct nodes, where plasma U-p532D3A8+ was still the most
important splitting variable that gave rise to two main branches (nodes 1 and 2 and nodes
3 and 4). According to a specific threshold of 10.79, 57%, and 96% of Aβ+ subjects branched
into node 3 (U-p532D3A8+ ≥ 10.79 and MMSE ≥ 26.5) and node 4 (U-p532D3A8+ ≥ 10.79
and MMSE < 26.5), respectively. In particular, nine of those MCI in node 4 developed AD
within 6–30 months. Of the aMCI in node 2 (U-p532D3A8+ < 10.79 and no APOEε4), 55%
were Aβ+ subjects who remained stable, apart from one who converted to AD. Node 1
(U-p532D3A8+ < 10.78 and APOEε4) was represented by 82% of A− /T− subjects (Figure 5a).
The diagnostic performance of the algorithm in identifying Aβ-positive status showed an
ROC with an AUC of 0.86 (95 CI%: 0.78–0.94) (Figure 5b).
T+/− ),
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Figure 5. U-p532D3A8+ plasma-based algorithm classification of Aβ status in PharmaCog/E-ADNI subjects. Schematic
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100% in identifying Aβ+ aMCI who will develop AD after 6–30 months (Figure 6).
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procedure, might meet this need. Overall, 86.67% of U-p532D3A8+ node assignments agreed
with clinical diagnosis (77.48–92.62%). This method allowed the automated stratification of
CN individuals and MCI at different degrees of AD risk. Plasma U-p532D3A8+ was found
more relevant for identifying low-AD-risk subjects, providing a tool to be used in the COU
in primary care settings.
U-p532D3A8+ validation will require cohorts well-characterized in term of APOε4
status, CSF, and/or PET scan Aß [7,9]. As misdiagnosis rates could exceed 20% [48],
we also tested plasma U-p532D3A8+ in PharmaCog/E-ADNI samples. The aMCI of the
PharmaCog/E-ADNI study, stratified according to the A/T multimodal classification
scheme, highlighted a good correspondence between the high levels of U-p532D3A8+ and
AD-associated brain pathology (Figure 4). In addition, the RT based on U-p532D3A8+
combined with APOEε4 genotype and MMSE further showed robust performance in
distinguishing aMCI classified as A+ /T+/− versus A− /T− (AUC of 0.86), suggesting Up532D3A8+ in plasma reflects what is occurring in the brain. The algorithm was also able
to show high prognostic performance in identifying Aβ+ -AD converters (AUC of 0.92).
Correspondingly, U-p532D3A8+ levels could be complementary to other AD biomarkers,
such as CSF or plasma Aß [10,49] and therefore could be included in a panel of plasma
biomarkers, supporting a personalized AD diagnosis.
Machine learning has been of interest in the biomarkers research of complex diseases
as a platform that can harvest information from biochemical and clinical sources into
an integrated system [50]. Here, we trained different RTs whose differences in terms
of thresholds were justified by the different outcomes used in the analysis (i.e., AD vs.
non-AD; A− /T− vs. A+ /T−/+ ). The algorithm was able to highlight the relevance of
U-p532D3A8+ in AD since, in all the datasets used, plasma U-p532D3A8+ is the first splitting
variable requested by the algorithm to describe AD using statistical language.
It is noteworthy that the application of machine learning to early detection and
automated classification of Alzheimer’s disease has recently gained considerable attention
because it allows the integration of big and deep biomedical data. The ability to deal with
“big data science” accompanied by the implementation of integrative disease is a crucial
starting step within a precision medicine strategy [9]. On the other hand, it is important to
be aware of the problem of overfitting that occurs when the learning algorithm describes the
random error or noise instead of the underlying data relationship. For this reason, in this
study, Bootstrap Method and cross-validated prediction have been applied to strengthen
the robustness of data obtained.
The evidence of U-p532D3A8+ expression in disease progression warrants further investigation of its role in AD pathogenesis. From a mechanistic point of view, a possible
link between the p53 conformational variant and Aβ has been suggested by investigating HIPK2–p53 signaling in different in vitro studies [21,51]. When Aβ is present at
nanomolar levels, throughout the inhibition of HIPK2, it induces the expression of metallothionein 2A, which, endowed with Zn-chelating activity, sequesters metals from the
DNA-binding-domain of p53 and induces its conformational changes, which in turn inhibits its activity [21]. In addition, a low-grade pro-oxidant environment, instead activating
p53 intracellular pathways, affects its tertiary structure, inducing conformational changes
and the loss of its activity [13,52,53]. Since p53 regulates a heterogeneous repertoire of
biological functions [43,44], including neuronal outgrowth and neuronal connectivity
protection [14,21], regulation of innate immunity [54], and redox homeostasis [21,55,56],
we hypothesize that the expression of this conformational variant in the early stage of
the disease might contribute to synapse dysfunction, inflammation, and oxidative stress.
Therefore, p53-misfolding variants might represent a signature of early AD pathological
events, including Aß accumulation, and redox imbalance and immune activation, leading eventually to oxidative stress and chronic inflammation, respectively. The precision
medicine paradigm for AD biomarker discovery has highlighted the importance of assay
development.
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